Vallon Pharmaceuticals, Inc. (VLON) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Philadelphia, PA, United States. The current CEO is David C. Baker.
VLON has IPO date of 2021-02-10, 2 full-time employees, listed on the NASDAQ Capital Marke.
Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. Its lead investigational product candidate is ADAIR, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The company is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.
